Application of CRISPR–cas-based technology for the identification of tuberculosis, drug discovery and vaccine development

Liqin Shi,Ruiqi Gu,Jinzhao Long,Guangcai Duan,Haiyan Yang
DOI: https://doi.org/10.1007/s11033-024-09424-6
IF: 2.7422
2024-03-30
Molecular Biology Reports
Abstract:Tuberculosis (TB), which caused by Mycobacterium tuberculosis , is the leading cause of death from a single infectious agent and continues to be a major public health burden for the global community. Despite being the only globally licenced prophylactic vaccine, Bacillus Calmette-Guérin (BCG) has multiple deficiencies, and effective diagnostic and therapeutic options are limited. Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas (CRISPR-associated proteins) is an adaptive immune system that is found in bacteria and has great potential for the development of novel antituberculosis drugs and vaccines. In addition, CRISPR-Cas is currently recognized as a prospective tool for the development of therapies for TB infection with potential diagnostic and therapeutic value, and CRISPR-Cas may become a viable tool for eliminating TB in the future. Herein, we systematically summarize the current applications of CRISPR–Cas-based technology for TB detection and its potential roles in drug discovery and vaccine development.
biochemistry & molecular biology
What problem does this paper attempt to address?